GO:0072562 blood microparticle: Components, Assembly and Research Methods

Blood microparticles (GO:0072562) are phospholipid microvesicles released from the plasma membrane of various blood and vascular cells, including platelets, red blood cells, endothelial cells, and leukocytes. Unlike exosomes, they are free of nucleic acids and are characterized by the presence of membrane receptors and other proteins typical of the parental cell. Since their discovery, blood microparticles have moved from being considered mere cellular debris to being recognized as key mediators of intercellular communication, coagulation, and inflammation. Their small size and heterogeneous composition make them challenging to study, but they hold significant promise as biomarkers and therapeutic targets in cardiovascular and hematological diseases. For researchers, understanding the biology of blood microparticles is essential because they are implicated in a wide range of physiological and pathological processes, from hemostasis and thrombosis to cancer progression and neurodegeneration. The QuickGO definition emphasizes that these microvesicles contain membrane receptors and other proteins characteristic of the parental cell, which allows them to interact specifically with target cells and tissues. This article provides a comprehensive overview of the composition, biogenesis, molecular mechanisms, and research methodologies associated with blood microparticles, with a focus on how CRISPR-based models can accelerate discovery in this field. Recent advances in proteomics and imaging have begun to unravel the complex cargo of blood microparticles, revealing that they carry not only surface markers but also bioactive lipids and cytoplasmic proteins that can alter the phenotype of recipient cells. As the field moves toward clinical translation, robust and standardized methods for isolation and characterization are critical. This article synthesizes current knowledge based on authoritative QuickGO data and verified PubMed literature to support both basic and translational research on blood microparticles.

According to the Gene Ontology, blood microparticle (GO:0072562) is a phospholipid microvesicle derived from any of several cell types, such as platelets, blood cells, endothelial cells, or others. It contains membrane receptors as well as other proteins characteristic of the parental cell. Microparticles are heterogeneous in size and are characterized as microvesicles free of nucleic acids. In simpler terms, blood microparticles are small membrane-bound packets released by blood and vessel cells that carry a snapshot of the parent cell's surface and can travel through the circulation to deliver signals to other cells.

Blood microparticles are important because they act as circulating messengers that can modulate coagulation, inflammation, and vascular function. They are implicated in the pathogenesis of atherothrombotic diseases, hemorrhage, and other conditions, and they hold potential as biomarkers for disease diagnosis and prognosis. Understanding their biology is therefore critical for developing new therapeutic strategies and diagnostic tools.

The following genes and proteins are key players in the biogenesis, composition, and function of blood microparticles, based on published literature.

The biogenesis and release of blood microparticles are regulated by various signaling pathways, including those involving calcium influx, cytoskeletal remodeling, and activation of kinases such as ROCK and PKC. In platelets, thrombin and collagen stimulate microparticle formation through GPVI and PAR receptors. In red blood cells, oxidative stress and complement activation can induce microparticle release. Tissue factor and TFPI also modulate the procoagulant activity of microparticles. Additionally, lipid raft integrity and flotillin-1 are important for microparticle formation.

Elevated levels of blood microparticles, particularly platelet- and endothelial-derived, are associated with atherothrombotic diseases such as myocardial infarction and stroke. They contribute to thrombus formation by exposing phosphatidylserine and tissue factor, and by promoting platelet-leukocyte aggregation. Targeting microparticle-mediated pathways is a potential therapeutic strategy.

Red blood cell-derived microparticles have been shown to limit hematoma growth in intracerebral hemorrhage, suggesting a protective role in hemostasis. This contrasts with their potential harmful effects in thrombosis, highlighting context-dependent functions.

Cellular microparticles are elevated in subarachnoid hemorrhage and may serve as biomarkers for disease severity and outcome. Their role in neuroinflammation and vasospasm is an active area of research.

Blood microparticles can promote cancer progression by transferring oncogenic proteins and promoting angiogenesis, and they are involved in chronic inflammatory conditions. Their cargo reflects the tumor microenvironment, making them potential liquid biopsy markers.

Flow cytometry is widely used to characterize blood microparticles based on surface markers such as CD41, CD235a, and annexin A5 binding. It allows quantification and phenotyping of microparticles from different cellular origins.

Mass spectrometry-based proteomics enables comprehensive profiling of microparticle cargo, revealing parental cell proteins and potential biomarkers. Pre-analytical variables such as centrifugation and storage must be carefully controlled.

NTA measures the size and concentration of microparticles in suspension, providing insights into their heterogeneity. It is often combined with fluorescence detection for specific markers.

Functional assays such as thrombin generation and endothelial cell adhesion assess the procoagulant and proinflammatory activities of microparticles. These assays are critical for linking microparticle composition to biological function.

Researchers studying blood microparticle-related genes often need to determine whether a candidate gene is causally involved in microparticle biogenesis, cargo selection, or function. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this discovery process, from knockout to knock-in and library screening.

Blood microparticles (GO:0072562) are heterogeneous phospholipid microvesicles that play diverse roles in hemostasis, thrombosis, inflammation, and intercellular communication. Their unique composition, reflecting parental cell proteins and lipids, makes them valuable biomarkers and therapeutic targets. Advances in CRISPR-based models and proteomic technologies are accelerating our understanding of microparticle biology and its implications for human disease. Continued research into the molecular mechanisms governing microparticle biogenesis and function will likely yield new diagnostic and therapeutic opportunities.